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Abstract
The molecular epidemiology of 32 non-duplicate, CTX-M-15
extended-spectrum beta-lactamase (ESBL)-producing Escherichia
coli strains, isolated from clinical samples, was investigated. Mul-
tilocus sequence typing revealed multiple sequence type clonal
complexes: ST131 (12), ST405 (4), ST638 (3), ST38 (2), ST827
(2), ST224 (1), ST648 (1), ST46 (1) and two new sequence type
clonal complexes (1845 and 1848) in 22 pulsed ﬁeld gel electro-
phoresis clusters. The blaCTX-M-15 gene was located on conjuga-
tive IncF plasmids. This is the ﬁrst report of the worldwide
emerging clonal complex ST131 linked to blaCTX-M-15 in Tanzania
and demonstrates the need for constant surveillance in develop-
ing countries to prevent the spread of these multiresistant iso-
lates.
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Extended-spectrum beta-lactamases (ESBLs) are the predomi-
nant resistance enzymes among enterobacteriaceae and most
of the beta-lactamases described to date are plasmid-encoded
enzymes [1,2]. CTX-M is a recently described family of
ESBLs. These enzymes hydrolyze cefotaxime more effectively
than ceftazidime [3] and are also able to hydrolyze cefepime
with high efﬁciency. The blaCTX-M-15 allele is considered to be
the predominant allele worldwide [4,5]. Extensive studies
investigating the association of the multilocus sequence typing
(MLST) clonal complex ST131 and blaCTX-M-15 have been
reported from Canada, India, Kuwait, France, Switzerland,
Portugal, Spain, Korea and Japan; worldwide dissemination of
blaCTX-M-15 seems to be linked to this clonal complex, which
is situated in the phylogenetic group B2 [4,5].
Two studies revealed that CTX-M enzymes were present
among Enterobacteriaceae in a few isolates in Tanzania [6,7].
However, no study has investigated molecular characteristics
of Escherichia coli ESBL-producing isolates in detail from this
region of the world. For the ﬁrst time we report the
existence of the ST131 and multiple other sequence type
(ST) clones carrying blaCTX-M-15 in a single tertiary hospital in
Tanzania, East Africa.
A total of 32 consecutive antimicrobial-resistant Escherichia
coli clinical isolates were recovered from various wards and
clinics in a tertiary hospital in Tanzania. Of these, 27 were
from inpatients who had been on the ward for more than
72 h when the specimens were collected, whereas ﬁve
strains were obtained from outpatients. Strains were identi-
ﬁed as E. coli using in-house biochemical proﬁles [8]. Sus-
ceptibility patterns to ampicillin, amoxicillin/clavulanic acid,
sulphamethaxazole/trimethoprim, tetracycline, gentamicin,
ciproﬂoxacin, ceftriaxone, cefotaxime, cefepime and merope-
nem were determined by disk diffusion [9]; a disk synergy
test was performed to detect ESBL production [8]. Escherichi-
a coli ATCC 25922 was used as the quality control strain.
PCR ampliﬁcation of bla genes (blaTEM, blaSHV and blaCTX-M)
was performed using primers and methods described previ-
ously [10]. All PCR products were sequenced (LGC genom-
ics GmbH, Berlin, Germany) and the resulting sequences
were compared with known sequences using DNASTAR soft-
ware (DNASTAR Inc, Madison, WI, USA) and the Basic
Local Alignment Search Tool (BLAST, National Center for
Biotechnology Information, Bethesda, MA, USA).
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To determine the location of ESBL genes, conjugation
experiments were carried out as described previously [11]
with 15 isolates as donors and Escherichia coli CC118 (RifR,
StrR, Lac-, plasmid-free) as a recipient strain. In all trans-
conjugants, plasmids were sized using S1-nuclease digestion
as described previously [11,12] followed by Southern blotting
and hybridization using digoxygenin (DIG)-labelled blaCTX-M-15
amplicon probes (DIG High Prime DNA labelling and Detec-
tion Starter Kit II, Roche, Mannheim, Germany). PCR-based
replicon typing was performed with all isolates and trans-
conjugants using primers for the FIA, FIB, FII, FrepB, I1 and
N replicons [13].
PFGE analysis was performed as previously described using
XbaI (New England Biolabs, Ipswich, MA, USA) [14]. Multilo-
cus sequence typing was carried out as recommended (http://
mlst.ucc.ie/mlst/dbs/Ecoli). The phylogenetic groups of these
isolates were determined by a previously described PCR-based
method [15] and serotyping was performed on ST 131 strains.
Overall, 24.2% of all Escherichia coli isolates from this hos-
pital were found to be ESBL producers [8]. In this study all
No       Ward      Specimen              Phy      ESBL                      Inc                ST             Cluster
X
FIG. 1. Pulsed ﬁeld gel electrophoresis (PFGE) dendogram of CTX-M-15 producing E. coli. Heterogeneity of the 32 E. coli extended-spectrum
beta-lactamase (ESBL) producers is seen on the dendogram. The diagram also shows the isolate number, wards, specimen, ESBL allele, incompat-
ibility groups, sequence type, clonal complex and the PFGE cluster. The solid line X indicates a similarity level of 0.8, revealing 22 clusters (X1–
X22). MOPD, medical outpatient department; NU, neonatal unit; CTC, care and treatment clinic; GOPD, gynaecological outpatient department;
NICU, neonatal intensive care unit; (E4,E8,C9,E9,C6, J5), surgical wards; VIP, ﬁrst class ward. Analysis was performed using GelCompar 11 soft-
ware (Applied Maths, Gent, Belgium).
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32 isolates were found to be resistant to cefotaxime
(MIC > 30 mg/L) and showed the classic ESBL phenomenon
on disk synergy test. The rate of resistance to non-beta-lac-
tam antibiotics tested was 100% to tetracycline, 93% to sul-
phamethaxazole/trimethoprim and 84% resistance to
gentamicin and ciproﬂoxacin. This poses a serious challenge
for the treatment of such infections due to the limited
choice of antibiotics in developing countries. All isolates
were found to carry blaCTX-M-15, while eight isolates (25%)
also carried blaTEM-1. In all isolates tested, blaCTX-M-15 was
linked to an ISEcp1 element. [16]. As described in other
studies that involve clinical isolates, 24 (75%) of the isolates
were assigned to the phylogenetic group B2 [5]. As demon-
strated in previous studies [4,5,11], multiple clones were
seen on PFGE and using a similarity level (SAB) of 0.8, 22
clusters (X1–X22) could be created among 32 isolates
(Fig. 1). With a similarity index of >0.99, three small out-
breaks were observed (clusters X2, X3 and X11), occurring
on paediatric wards and a surgical ward. MLST revealed an
atypical high diversity of ST carrying blaCTX-M-15 in this single
hospital in Tanzania, which contrasts with ﬁndings from pre-
vious reports [17–19]. Many of the Escherichia coli carrying
blaCTX-M-15 from different countries in Europe and North
America are homogenously grouped into the E. coli O25:H4-
ST131 [4,5,18], which was also the commonest group in this
study (40%). Most of the STs (ST131, ST405, ST638, ST648,
ST827 and ST224) in our study have been reported to carry
blaCTX-M-15. ST1845, ST1848, ST46 and ST455 are reported
here for the ﬁrst time to be associated with blaCTX-M-15. ST
648 has been found to be common in birds and close prox-
imity to birds can be a risk factor for infection [20]. Only
two isolates were grouped in the phylogenetic group D and
these were found to be associated with ST405, thus support-
ing previous observations [5].
PCR-based replicon typing revealed that FIA, FIB, FII and
FrepB were present in 30 clinical isolates and transconjugants
in various combinations. The commonest combination was
FIA- FIB, which was demonstrated in 14 (47%) cases. IncFII
was found in eight (26%) cases. The blaCTX-M-15 gene in this
study is carried on multiple, conjugative IncF plasmids, with
estimated plasmid sizes ranging from 50kb to 291kb (Table 1).
The commonest plasmid was 291 kb in size and was found in
six (40%) transconjugants. We demonstrated the presence of
multiple conjugative IncF plasmids carrying this allele, with
conjugation frequencies ranging from 10)3 to 10)7 per donor
cell (Table 1). The majority of isolates displayed multidrug
resistance, being also resistant to gentamicin, tetracycline,
ciproﬂoxacin and sulphamethaxazole/trimethoprim, whereby
the gentamicin resistance was transferrable in most cases.
These results provide ﬁrst evidence for the existence of the
ST131 strains harbouring the CTX-M-15 allele in East Africa,
and indicate a need for constant surveillance to study the
epidemiology and diversity of these ESBL-producing Escherichia
coli isolates in developing countries, as the scope of the
problem seems to be wider than previously suspected.
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TABLE 1. Characteristics of Escherichia coli selected as donors from different pulsed ﬁeld gel electrophoresis clusters
Serial no. Isolate no. Incompatability group Sequence type Conjugation frequency Calculated plasmid size Transferable resistance
1 02 FIA,FIB ST131 10)7 291 kb GM
2 18 FIB ST405 2.7*10)4 50 kb GM,SXT,TET
3 22 FIB ST131 2.8*10)4 291 kb GM,SXT,TET
4 32 FIA,FIB ST638 2.2*10)4 50 kb GM,SXT,TET
5 76 FIA,FIB ST224 10)4 194 kb GM,SXT
6 140 FIB ST827 10)4 242 kb SXT,TET
7 170 FrepB ST648 10)5 97 kb GM
8 187 FIA,FIB ST405 10)3 200 kb GM,SXT
9 178 FIB ST131 10)4 242 kb Beta-lactams
10 181 FIB ST38 10)6 291 kb GM,SXT,TET
11 51 FIA,FIB NT 10)5 291 kb GM,SXT,TET
12 215 FIA,FIB ST405 10)7 145 kb GM,SXT,TET
13 096 FIA,FIB ST131 4*10)4 242 kb Beta-lactams
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